Halozyme Therapeutics and AbbVie have signed global collaboration and licensing agreement, which involves both companies developing and commercialising products combining proprietary AbbVie compounds with Halozyme’s Enhanze platform.

Under the deal, Halozyme will secure an initial $23m payment from AbbVie, in addition to milestone payments of around $130m for meeting each nine collaboration targets.

The deal will also allow Halozyme to receive tiered royalties from AbbVie, if products under the collaboration are commercialised.

"AbbVie joins a growing number of top pharmaceutical and biotech companies partnering with Halozyme to develop new formulations that will benefit patients worldwide."

Halozyme Therapeutics president and CEO Dr Helen Torley said: "We are pleased that AbbVie, a global leader in the development of novel therapeutics, has chosen Halozyme’s Enhanze platform to augment their development pipeline.

"AbbVie joins a growing number of top pharmaceutical and biotech companies partnering with Halozyme to develop new formulations that will benefit patients worldwide."

The Enhanze is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20), which temporarily degrades hyaluronan, a chain of natural sugars in the body, to assist in the dispersion and absorption of other injected therapeutic drugs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AbbVie will use the technology for more rapid delivery of injectable medications through subcutaneous delivery.

The Enhanze platform is claimed to benefit subcutaneous biologics by reducing the need for multiple injections.

According to Halozyme, the rHuPH20 claimed to remove traditional limitations on the volume of biologics that can be delivered subcutaneously and by using it, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously.